Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

2.1K
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
2.1K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

2.5K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.5K
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

1.5K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.5K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.7K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.7K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

4.0K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.0K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

2.8K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.8K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Medial prefrontal cortex and ventrolateral orbitofrontal cortex inputs into the ventrolateral periaqueductal grey region differentially regulate pain and anxiety like behavior.

Neuroscience·2026
Same author

Gating effects of a Cav2.3 calcium channel variant linked to developmental and epileptic encephalopathy.

Neuroscience·2026
Same author

Emerging Pharmacological Strategies for Trigeminal Neuralgia.

CNS drugs·2026
Same author

Practical and divergent electrochemical access to thiocarbamoyl fluorides and N-trifluoromethyl amines from secondary amines.

Nature communications·2026
Same author

Electrochemical Trideuteromethylation with AcOD-<i>d</i><sub>4</sub>: A Route to CD<sub>3</sub>-Labeled Building Blocks.

Organic letters·2026
Same author

Probing 3-Amino-2H-Azaindazoles as Allosteric Inhibitors of the Protein Tyrosine Phosphatase SHP2.

ChemMedChem·2026

相关实验视频

Updated: Mar 17, 2026

One-channel Cell-attached Patch-clamp Recording
13:07

One-channel Cell-attached Patch-clamp Recording

Published on: June 9, 2014

25.6K

具有胺功能的六基诺林:具有通道阻断活性的有希望的支架

Ebru Koçak Aslan1, Kevin Lam2, Sun Huang3

  • 1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey.

Drug development research
|March 15, 2026
PubMed
概括
此摘要是机器生成的。

新的六氨基胺 (HHQ) 显示出作为心血管和疼痛疾病的通道阻断剂的潜力,比传统的以为基础的药物提供更好的代谢稳定性.

关键词:
汉茨赫的合成方法这是一种二皮里丁二.在对抗分离的过程中.代谢稳定性 代谢稳定性分子建模分子建模补丁紧固件 补丁紧固件

更多相关视频

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
10:20

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

Published on: November 11, 2016

9.0K
Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
07:42

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Published on: October 18, 2018

6.7K

相关实验视频

Last Updated: Mar 17, 2026

One-channel Cell-attached Patch-clamp Recording
13:07

One-channel Cell-attached Patch-clamp Recording

Published on: June 9, 2014

25.6K
Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
10:20

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

Published on: November 11, 2016

9.0K
Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
07:42

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Published on: October 18, 2018

6.7K

科学领域:

  • 药用化学 医学化学
  • 药理学 药理学是指药理学的学科.
  • 心血管研究研究心血管研究

背景情况:

  • 六基诺林 (HHQ) 衍生物被认为具有多种药理学作用.
  • 1,4-二皮里丁 (DHP) 是通道阻断剂的核心药物,对于控制心血管疾病和疼痛至关重要.
  • 目前的DHP利用功能;探索生物异胺替代品是新疗法的关键.

研究的目的:

  • 合成具有或胺功能的新型HHQ化合物 (EM1-EM15).
  • 研究这些化合物对L型 (Cav1.2) 和T型 (Cav3.2) 通道的影响.
  • 评估含胺HHQs作为下一代通道阻断剂的潜力.

主要方法:

  • 新型HHQ和胺衍生物 (EM1-EM15) 的合成.
  • 全细胞补丁电生理学评估通道阻断活性.
  • 用于结合模式分析的分子对接和动力学模拟.
  • 在实验室中使用小鼠显微体进行代谢稳定性测试.

主要成果:

  • 含胺的HHQ在L型和T型通道上都表现出显著的阻断活性,尽管其效果不如类对应物那么强大.
  • 确定EM4的 (R) - 反体是通道阻塞的主要贡献者.
  • 分子模拟揭示了Cav1.2中的结合模式类似于阿姆洛迪平,并确定了Cav3.2.2中的结合部位.
  • 与相比,胺衍生物表现出更高的代谢稳定性.

结论:

  • 带有胺基组的六基诺林支架代表了开发新型通道阻断剂的有希望的途径.
  • 这些化合物显示出治疗心血管疾病和疼痛的潜力,增强了代谢稳定性.
  • (R) 异构体对于观察到的通道阻断活性至关重要.